Merck, also known as MSD, has announced a partnership with Seattle Genetics, the biotech and oncology specialist. The companies have reached an agreement to collaborate on the development and marketing of Seattle’s Ladiratuzumab Vedotin antibody-drug conjugate (ADC). The ADC is currently undergoing Phase II trials for solid tumors including breast cancer. Further work on the drug will test the drug’s effectiveness as both a solo treatment and combined with Merck’s Keytruda PD-1 inhibitor in breast cancer and other solid tumor types.
News
Who Should be Vaccinated First?
The pandemic has led to a race to create a vaccine for COVID-19. While there seem to be some effective solutions on the horizon, the question is who should be given the COVID-19 vaccine first? People around the world continue to have their everyday lives changed by the pandemic, with many people becoming seriously ill and dying. The harm done to the economies of every country is a problem that will continue to do damage for many years.
Persistent Symptoms After Coronavirus Recovery
The global pandemic has seen unprecedented numbers of people around the world struck down with symptoms including fatigue, breathing difficulties, fever, loss of smell or taste, and more. These symptoms have often become far more serious in people from higher-risk groups.While the majority of people will recover from the worst of these symptoms, there seems to be some evidence of some symptoms persisting after COVID-19 coronavirus recovery. Evidence is fairly limited at the moment, but more studies are being undertaken to learn the size of this problem.
MMR Vaccine – Reason Children are Less Influenced by COVID-19
The measles, mumps and rubella (MMR) vaccine can protect children from coronavirus disease 2019 (COVID-19), according to a new hypothesis from researchers at Kaunas University of Technology.
Hope for Patients with Migraine
Migraine is not just a headache when the pain and symptoms disappear. It affects the daily lives of patients and can completely change their lifestyle. Migraine symptoms can be debilitating and last up to 72 hours. Migraine is a common disease that affects about 38 million people in the United States and about 10% of people worldwide.
